Respiratory syncytial virus infection: survival experience in a cohort of children inpatients.

The objective of this study was to assess the survival experience of children hospitalized with laboratory-confirmed respiratory syncytial virus (RSV) infection due to bronchiolitis. This was a nationwide retrospective cohort study conducted in Mexico. We analyzed data from 436 children aged 5 years and younger, with symptom onset between August 2021 and November 2022. The Kaplan–Meier method was used to compute survivor functions and their 95% confidence intervals (CI). High survival rates were observed, particularly within the first three weeks of hospital admission. The 3-day survival rate was 99.8% (CI 98.4–99.9%), which decreased to 98.9% (CI 96.5–99.7%), 97.5% (CI 91.9–99.3%), 86.7% (CI 48.2–97.2%), and 69.4% (CI 24.2–91.0%) on days 7, 14, 21, and 28 of hospital stay, respectively. We documented a total of 5 fatal outcomes, resulting in a mortality rate of 2.1 (95% CI 0.9–5.1) per 1,000 person-days. Our study analyzed a large cohort of pediatric patients with bronchiolitis caused by RSV infection, providing valuable insights into the in-hospital progression of this disease. [ABSTRACT FROM AUTHOR]

Copyright of Public Health (Elsevier) is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)